These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 12733312)

  • 1. [Pharmacologic innovations, the fluoroquinolone model].
    Bergogne-Bérézin E
    Presse Med; 2003 Mar; 32(10):466-9. PubMed ID: 12733312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fluoroquinolone benchmarking in relation to pharmacokinetic and pharmacodynamic parameters.
    Paladino JA; Callen WA
    J Antimicrob Chemother; 2003 May; 51 Suppl 1():43-7. PubMed ID: 12702703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Animal model pharmacokinetics and pharmacodynamics: a critical review.
    Andes D; Craig WA
    Int J Antimicrob Agents; 2002 Apr; 19(4):261-8. PubMed ID: 11978497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Challenges in assessing microbial susceptibility and predicting clinical response to newer-generation fluoroquinolones.
    Segreti J; Jones RN; Bertino JS
    J Ocul Pharmacol Ther; 2012 Feb; 28(1):3-11. PubMed ID: 21999341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [New development in clinical pharmacology of anti-infective agents].
    Bergogne-Bérézin E
    Presse Med; 1998 Dec; 27 Suppl 5():34-41. PubMed ID: 9879335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pre-clinical studies of a new quinolone (UB-8902) against Acinetobacter baumannii resistant to ciprofloxacin.
    López-Rojas R; Sánchez-Céspedes J; Docobo-Pérez F; Domínguez-Herrera J; Vila J; Pachón J
    Int J Antimicrob Agents; 2011 Oct; 38(4):355-9. PubMed ID: 21820876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New concept and a theoretical consideration of the mechanism-based pharmacokinetics/ pharmacodynamics (PK/PD) modeling for antimicrobial agents.
    Sato N; Suzuki H; Hayashi H; Shibasaki S; Sugano T; Maebashi K; Kurosawa T; Shiomi M; Ogata H
    Jpn J Antibiot; 2008 Oct; 61(5):314-38. PubMed ID: 19260351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update.
    Mouton JW; Dudley MN; Cars O; Derendorf H; Drusano GL
    J Antimicrob Chemother; 2005 May; 55(5):601-7. PubMed ID: 15772142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gap analysis of pharmacokinetics and pharmacodynamics in burn patients: a review.
    Steele AN; Grimsrud KN; Sen S; Palmieri TL; Greenhalgh DG; Tran NK
    J Burn Care Res; 2015; 36(3):e194-211. PubMed ID: 25942648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploration of optimal dosing regimens of vancomycin in patients infected with methicillin-resistant Staphylococcus aureus by modeling and simulation.
    Lim HS; Chong YP; Noh YH; Jung JA; Kim YS
    J Clin Pharm Ther; 2014 Apr; 39(2):196-203. PubMed ID: 24428720
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical pharmacology of the fluoroquinolones: studies in human dynamic/kinetic models.
    Schentag JJ
    Clin Infect Dis; 2000 Aug; 31 Suppl 2():S40-4. PubMed ID: 10984327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Continuing education: alternative approaches to optimizing antimicrobial pharmacodynamics in critically ill patients.
    Winterboer TM; Lecci KA; Olsen KM
    J Pharm Pract; 2010 Feb; 23(1):6-18. PubMed ID: 21507788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical investigation on administration method of gatifloxacin based on PK/PD theory].
    Mikamo H; Tanaka K; Watanabe K; Tamaya T; Izumi K
    Jpn J Antibiot; 2006 Oct; 59(5):364-72. PubMed ID: 17180805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics, pharmacodynamics and therapeutics of pradofloxacin in the dog and cat.
    Lees P
    J Vet Pharmacol Ther; 2013 Jun; 36(3):209-21. PubMed ID: 23406008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics-pharmacodynamics of gatifloxacin in a lethal murine Bacillus anthracis inhalation infection model.
    Ambrose PG; Forrest A; Craig WA; Rubino CM; Bhavnani SM; Drusano GL; Heine HS
    Antimicrob Agents Chemother; 2007 Dec; 51(12):4351-5. PubMed ID: 17875992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical implications of pharmacokinetics and pharmacodynamics of fluoroquinolones.
    Wispelwey B
    Clin Infect Dis; 2005 Jul; 41 Suppl 2():S127-35. PubMed ID: 15942879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Maximizing efficacy and reducing the emergence of resistance.
    Wise R
    J Antimicrob Chemother; 2003 May; 51 Suppl 1():37-42. PubMed ID: 12702702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics/Pharmacodynamics models of veterinary antimicrobial agents.
    Luo W; Chen D; Wu M; Li Z; Tao Y; Liu Q; Pan Y; Qu W; Yuan Z; Xie S
    J Vet Sci; 2019 Sep; 20(5):e40. PubMed ID: 31565887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Application of pharmacokinetics and pharmacodynamics to antimicrobial therapy of community-acquired respiratory tract infections.
    Calbo E; Garau J
    Respiration; 2005; 72(6):561-71. PubMed ID: 16354997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacodynamics: relation to antimicrobial resistance.
    Rybak MJ
    Am J Med; 2006 Jun; 119(6 Suppl 1):S37-44; discussion S62-70. PubMed ID: 16735150
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.